AUROBINDO

February 9, 2021

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir,

Sub: Analyst / Investor call

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that an analyst / investor call on the Unaudited Financial Results of the Company for the third quarter and nine months period ended 31st December 2020 is scheduled on 11th February 2021 at 08:30 hrs.

Please find attached the dial-in details of the call.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl: as above

9th February 2021, Hyderabad, India

Aurobindo Pharma Limited Q3 FY20-21 earnings call is scheduled on 11th February 2021 at 08:30 hrs

The dial-in details to participate in the call are as under. You may also pre-register in the call through the link mentioned below.

Please dial the below number at least 5 minutes prior to the conference schedule to ensure that you are connected to your call in time.	
Primary Number:	+91 22 6280 1437 / +91 22 7115 8825
The number listed above are universally accessible from all networks and all countries.	
Local Access Number:	+91-70456 71221 *Available all over India*
Toll Free Number:	USA: 1866 746 2133 UK: 0808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Pre-register Link (URL)	https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=5343979&linkSecurityString=11118a0cb2

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:

Krishna Kiran
Investor Relations,
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com